#United States #New York #Faruqi & Faruqi #ImmunityBio #IBRX

ImmunityBio Class Action Update

Investors in ImmunityBio, Inc. (IBRX) are being alerted by the prominent securities law firm, Faruqi & Faruqi, LLP, about a significant deadline approaching for a class action lawsuit. The deadline for seeking the role of lead plaintiff is set for May 26, 2026, which has attracted attention from current and former shareholders.

Overview of the Class Action

The legal proceedings center on claims that ImmunityBio, along with its executives, allegedly made misleading statements regarding the company's operational capacities, particularly about the drug Anktiva. These disclosures have led to a decline in share price, deeply impacting investors.

On January 23, 2026, ImmunityBio announced updated Phase 2 clinical results for their treatment of glioblastoma. Unfortunately, the results indicated that the median overall survival endpoint had not yet been reached, causing the company's stock to plunge by 12.13% the same day. This decline raised concerns regarding the validity of previous statements made by the company.

Faruqi & Faruqi's Senior Partner, James (Josh) Wilson, has emphasized the importance of contacting their office for those who suffered financial losses due to these developments. Whether a full-scale lawsuit or simply joining as a class member, all investors are encouraged to assess their legal rights and options.

Who Can Participate?

The class action is open to any investor who purchased ImmunityBio’s securities between January 19, 2026, and March 24, 2026. If you are eligible and are considering taking action, it’s important to consult legal experts who can guide you on whether stepping up as a lead plaintiff is the right move. Acting quickly will maximize your opportunities for recovery should the case proceed favorably for investors.

How to Get Involved

Interested investors can easily reach out to Faruqi & Faruqi, either via phone (877-247-4292 or 212-983-9330) or by visiting their official website. The firm also invites whistleblowers or former employees with inside information about ImmunityBio's conduct to make contact.

The role of the lead plaintiff is critical, as this person will represent the interests of all affected shareholders throughout the litigation process. To ensure equitable representation, investors can either choose their own counsel to help with this process or allow the firm to manage these details independently.

Conclusion

With the impending deadline of May 26, 2026, ImmunityBio investors must act promptly to protect their legal rights. The forthcoming class action may provide an avenue for recovery against the alleged misrepresentations made by the company’s leadership. Interested parties should gather pertinent documentation and engage with legal professionals to discuss potential claims.

By staying informed and taking action, shareholders can pursue justice and potentially recover losses sustained as a result of the company's choices. Faruqi & Faruqi remains dedicated to supporting investors through these challenging circumstances, ensuring they are well-informed and prepared for legal proceedings.

Attorneys at Faruqi & Faruqi emphasize the weight of this situation and are prepared to navigate the complexities involved in seeking redress for affected investors. Participation is an important step for anyone who believes they have been wronged.